Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California, with news flow centered on development of its investigational Hemopurifier device. Company announcements highlight progress in oncology and infectious disease programs, capital markets activity, and regulatory interactions that shape the outlook for AEMD stock.
Recent news releases describe Aethlon’s ongoing safety, feasibility, and dose-finding oncology trial in Australia, where the Hemopurifier is being evaluated in patients with solid tumors who have not responded to anti-PD-1 therapies. Updates have covered early observations on extracellular vesicles, microRNAs, and lymphocyte counts in initial cohorts, along with protocol amendments and site activity. The company also reports collaborations in Long COVID research, including preclinical data showing that its GNA affinity resin binds extracellular vesicles in Long COVID plasma and depletes EV-associated microRNAs linked to inflammatory pathways.
Investors following AEMD news will also see regular disclosures on financing transactions, such as public offerings and private placements of common stock, pre-funded warrants, and common stock purchase warrants. These items detail gross proceeds, warrant terms, and intended uses of capital for clinical trials, research and development, and working capital. Additional coverage includes patent issuances related to Long COVID and COVID-19-associated coagulopathy, Nasdaq listing compliance updates, and scheduling of quarterly financial results and conference calls.
This news page aggregates Aethlon Medical’s press releases and related coverage so readers can review clinical updates, scientific publications, financing events, and regulatory milestones in one place. For those tracking AEMD, it offers a structured view of how the company communicates progress on the Hemopurifier and its broader development strategy over time.
Summary not available.
Summary not available.
Summary not available.
Aethlon Medical (NASDAQ: AEMD) reported its financial results for the third quarter ending December 31, 2022. The company continues developing the Hemopurifier®, focusing on cancer and life-threatening infectious diseases. A significant update includes a new oncology study set to initiate in Australia and the U.S. The company's cash balance stands at approximately $17.5 million, while operating expenses rose by 12% to roughly $2.85 million. Aethlon experienced a net loss of approximately $2.85 million, up from $2.53 million during the same period in 2021. The company did not record government contract revenue this quarter, impacting its financial results.
Summary not available.
Aethlon Medical, Inc. (NASDAQ: AEMD) announced it will release its financial results for Q3 ended December 31, 2022, on February 6, 2023, at 4:15 p.m. EST. Following the results, a conference call will take place at 4:30 p.m. EST for management to discuss financial outcomes and corporate developments. The company focuses on developing the Hemopurifier, a clinical-stage device aimed at treating cancer and life-threatening infectious diseases. The Hemopurifier has received FDA Breakthrough Device designation due to its potential to remove harmful viruses and exosomes from blood.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced its virtual presentation scheduled for February 2nd, 2023, at 10:00 AM ET, during the Sequire Biotechnology Conference. Led by Steven LaRosa, M.D., the presentation will outline the company's innovative medical technology aimed at treating cancer and severe infectious diseases. The biotechnology industry is projected to reach $727 billion by 2025, featuring over 6,500 US companies. Aethlon's main technology, the Hemopurifier, has received FDA Breakthrough Device designation and targets advanced cancer and life-threatening viral infections.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced a strategic agreement with NAMSA, a leading MedTech Contract Research Organization, to oversee clinical trials for its Hemopurifier device targeting cancer treatments. The trials will begin in Australia and include patients with various cancer tumors. Aethlon aims to expedite the clinical development of the Hemopurifier, which has shown promise in removing harmful exosomes and viruses from blood. The device is designated by the FDA as a Breakthrough Device for advanced or metastatic cancer therapies. This partnership is expected to enhance the efficiency and effectiveness of Aethlon's clinical research efforts.
Aethlon Medical, Inc. (AEMD) reported financial results for Q2 2022, with a net loss of approximately $3.8 million, a significant increase from $2.0 million in Q2 2021. Operating expenses rose to $3.67 million, up 71% year-over-year. The company has terminated its U.S. COVID-19 trial and head and neck cancer safety trial due to low patient enrollment, reallocating funds to advance the Hemopurifier in oncology research. As of September 30, 2022, Aethlon had a cash balance of $19.6 million and plans to launch a new oncology trial while engaging a new CRO in the U.S. and Australia.
Aethlon Medical (Nasdaq: AEMD) will announce its second-quarter financial results for the period ending September 30, 2022, on November 14, 2022, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST to discuss the results and corporate developments. The Hemopurifier, a breakthrough device, is being evaluated for treating cancer and infectious diseases. Notably, it has shown potential in removing harmful exosomes related to cancer and treating COVID-19 patients, demonstrating effectiveness in binding and removing the SARS-CoV-2 virus.